Peregrine Pharmaceuticals reported $181.2M in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Agenus AGEN:US USD -20385000 23.8M
Amgen AMGN:US USD 3.66B 8M
AstraZeneca AZN:LN USD 35.13B 798M
Biocryst Pharmaceuticals BCRX:US USD -242659000 29.43M
Bristol Myers Squibb BMY:US USD 32.67B 71M
Celldex Therapeutics CLDX:US USD 345.42M 19.68M
Eli Lilly And LLY:US USD 10.07B 1.53B
GlaxoSmithKline GSK:LN GBP 10.6B 1.45B
Immunogen IMGN:US USD 178.01M 71.82M
Intrexon XON:US USD 142.53M 86.88M
Karyopharm Therapeutics KPTI:US USD -140280000 23.94M
Macrogenics MGNX:US USD 122.96M 19.52M
Mannkind MNKD:US USD -237677000 9.38M
Merk MRK:US USD 44.46B 1.22B
Minerva Neurosciences NERV:US USD -14246000 5.86M
Newlink Genetics NLNK:US USD 67.71M 6.84M
Novartis NOVN:VX USD 60.82B 2.1B
Novavax NVAX:US USD -565985000 149.04M
Peregrine Pharmaceuticals PPHM:US USD 181.2M 2.2M
Repligen RGEN:US USD 1.84B 29.74M
Roche Holding ROG:VX 25.19B 700M
Xencor XNCR:US USD 722.7M 19.64M